Practice Apoptosis: When Partners Retire

Article

Kicking off the first in a series of podcasts, a noted healthcare consultant discusses how retirement can fracture a practice.

In today’s challenging environment, community oncology practices must devise new business models if they are to continue providing high quality care for patients while adequately compensating their physicians. Practices must also adapt to an environment in which professional-fee revenue plays an increasingly important role in reimbursing for care.

In short, busy community doctors need to create a sound business plan that complements the skills and needs of their partners. Building the right practice “chemistry” is tantamount to success. So, what happens when a partner, or two, decides to retire? In this podcast, noted healthcare consultant, Thomas A. Paivanas, discusses the realities, with the caveat, fortune favors a prepared mind.

Stay tuned for our next expert podcast: Martin Neltner talks about quality in cancer care, what it means to the busy practitioner as we move forward into our brave new world of healthcare…
 

           
 

Practice Apoptosis: When Partners Retire
Right mouse click and "Save As" to download

Related Videos
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Related Content
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer

April 30th 2024
Article

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Amivantamab/chemotherapy has been recommended for approval by the CHMP in advanced non–small cell lung cancer with EGFR exon 20 insertion mutations.

CHMP Promotes Positive Opinion of Amivantamab in EGFR Exon 20+ NSCLC

April 29th 2024
Article

Amivantamab/chemotherapy has been recommended for approval by the CHMP in advanced non–small cell lung cancer with EGFR exon 20 insertion mutations.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.

Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers

April 29th 2024
Article

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.

Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.

T-DXd Meaningfully Improves PFS Vs Chemo in HR+, HER2-Low Breast Cancer

April 29th 2024
Article

Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.